Does the media refer more to ABVX or ARQT?

In the previous week, Abivax had 22 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 26 mentions for Abivax and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Abivax's score of 0.03 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 3 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral Arcutis Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARQT or CYTK?

In the previous week, Cytokinetics had 5 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 9 mentions for Cytokinetics and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Cytokinetics' score of 0.25 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARQT or KRYS?

In the previous week, Krystal Biotech had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 8 mentions for Krystal Biotech and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Krystal Biotech's score of 0.56 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IBRX or ARQT?

In the previous week, ImmunityBio had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat ImmunityBio's score of -0.19 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Arcutis Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcutis Biotherapeutics (ARQT) Competitors

$21.54 +0.31 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$21.28 -0.26 (-1.23%)

As of 07:25 PM Eastern

Compare

ARQT vs. ABVX, PRAX, CYTK, KRYS, and IBRX

Should you buy Arcutis Biotherapeutics stock or one of its competitors? MarketBeat compares Arcutis Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcutis Biotherapeutics include Abivax (ABVX), Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Arcutis Biotherapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Arcutis Biotherapeutics has higher revenue and earnings than Abivax. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Arcutis Biotherapeutics	$376.07M	7.16	-$16.14M	-$0.03	N/A

In the previous week, Abivax had 22 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 26 mentions for Abivax and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Abivax's score of 0.03 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	3 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Abivax presently has a consensus target price of $130.08, indicating a potential upside of 28.12%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 57.85%. Given Arcutis Biotherapeutics' higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

47.9% of Abivax shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Abivax has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Summary

Arcutis Biotherapeutics beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Praxis Precision Medicines presently has a consensus price target of $572.72, indicating a potential upside of 126.15%. Arcutis Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 57.85%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe Praxis Precision Medicines is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Praxis Precision Medicines had 15 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 19 mentions for Praxis Precision Medicines and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Praxis Precision Medicines' score of -0.08 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher revenue and earnings than Praxis Precision Medicines. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	825.80	-$303.27M	-$13.37	N/A
Arcutis Biotherapeutics	$376.07M	7.16	-$16.14M	-$0.03	N/A

Praxis Precision Medicines has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Summary

Praxis Precision Medicines beats Arcutis Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Cytokinetics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Arcutis Biotherapeutics has higher revenue and earnings than Cytokinetics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.16	-$16.14M	-$0.03	N/A
Cytokinetics	$88.04M	95.97	-$784.96M	-$6.84	N/A

Arcutis Biotherapeutics has a net margin of -0.57% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Cytokinetics	-784.02%	N/A	-52.86%

Arcutis Biotherapeutics presently has a consensus target price of $34.00, suggesting a potential upside of 57.85%. Cytokinetics has a consensus target price of $99.30, suggesting a potential upside of 46.24%. Given Arcutis Biotherapeutics' higher possible upside, equities analysts clearly believe Arcutis Biotherapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Cytokinetics had 5 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 9 mentions for Cytokinetics and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Cytokinetics' score of 0.25 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Cytokinetics on 8 of the 15 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Krystal Biotech?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Arcutis Biotherapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Arcutis Biotherapeutics presently has a consensus price target of $34.00, indicating a potential upside of 57.85%. Krystal Biotech has a consensus price target of $324.11, indicating a potential upside of 7.41%. Given Arcutis Biotherapeutics' higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Krystal Biotech had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 8 mentions for Krystal Biotech and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat Krystal Biotech's score of 0.56 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.16	-$16.14M	-$0.03	N/A
Krystal Biotech	$389.13M	22.86	$204.83M	$7.48	40.34

86.3% of Krystal Biotech shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to Arcutis Biotherapeutics' net margin of -0.57%. Krystal Biotech's return on equity of 19.25% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Krystal Biotech	53.92%	19.25%	17.62%

Summary

Krystal Biotech beats Arcutis Biotherapeutics on 13 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

8.6% of ImmunityBio shares are held by institutional investors. 69.5% of ImmunityBio shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arcutis Biotherapeutics has a net margin of -0.57% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

ImmunityBio has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 98.05%. Arcutis Biotherapeutics has a consensus price target of $34.00, suggesting a potential upside of 57.85%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arcutis Biotherapeutics has higher revenue and earnings than ImmunityBio. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	66.29	-$351.40M	-$0.85	N/A
Arcutis Biotherapeutics	$376.07M	7.16	-$16.14M	-$0.03	N/A

In the previous week, ImmunityBio had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.86 beat ImmunityBio's score of -0.19 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ImmunityBio beats Arcutis Biotherapeutics on 9 of the 16 factors compared between the two stocks.

Get Arcutis Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARQT vs. The Competition

Export

Metric	Arcutis Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.66B	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-717.76	10.38	20.24	21.95
Price / Sales	7.16	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	13.90	8.04	10.28	6.78
Net Income	-$16.14M	$23.89M	$3.57B	$337.51M
7 Day Performance	0.33%	-5.97%	-1.43%	-2.72%
1 Month Performance	1.75%	2.78%	3.27%	1.87%
1 Year Performance	49.90%	36.26%	23.37%	26.61%

Arcutis Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARQT Arcutis Biotherapeutics	3.378 of 5 stars	$21.54 +1.5%	$34.00 +57.8%	+47.7%	$2.66B	$376.07M	N/A	150
ABVX Abivax	3.481 of 5 stars	$129.73 +2.6%	$137.15 +5.7%	+1,139.7%	$10.07B	N/A	N/A	61
PRAX Praxis Precision Medicines	2.873 of 5 stars	$357.13 +1.9%	$592.67 +66.0%	+470.0%	$9.77B	$8.55M	N/A	110
CYTK Cytokinetics	2.8956 of 5 stars	$77.15 +1.1%	$99.30 +28.7%	+121.3%	$9.49B	$88.04M	N/A	250	Options Volume
KRYS Krystal Biotech	3.3854 of 5 stars	$306.63 +1.3%	$324.11 +5.7%	+119.8%	$8.92B	$389.13M	40.99	210	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARQT) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ABVX, PRAX, CYTK, KRYS, and IBRX

How does Arcutis Biotherapeutics compare to Abivax?

Summary

How does Arcutis Biotherapeutics compare to Praxis Precision Medicines?

Summary

How does Arcutis Biotherapeutics compare to Cytokinetics?

Summary

How does Arcutis Biotherapeutics compare to Krystal Biotech?

Summary

How does Arcutis Biotherapeutics compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ABVX, PRAX, CYTK, KRYS, and IBRX

How does Arcutis Biotherapeutics compare to Abivax?

Which has higher earnings & valuation, ABVX or ARQT?

Does the media refer more to ABVX or ARQT?

Which has more volatility & risk, ABVX or ARQT?

Do analysts prefer ABVX or ARQT?

Do institutionals and insiders believe in ABVX or ARQT?

Is ABVX or ARQT more profitable?

Summary

How does Arcutis Biotherapeutics compare to Praxis Precision Medicines?

Do analysts recommend PRAX or ARQT?

Which has more risk & volatility, PRAX or ARQT?

Do institutionals & insiders have more ownership in PRAX or ARQT?

Does the media prefer PRAX or ARQT?

Which has stronger earnings & valuation, PRAX or ARQT?

Is PRAX or ARQT more profitable?

Summary

How does Arcutis Biotherapeutics compare to Cytokinetics?

Which has stronger valuation & earnings, ARQT or CYTK?

Is ARQT or CYTK more profitable?

Do analysts recommend ARQT or CYTK?

Does the media refer more to ARQT or CYTK?

Which has more volatility & risk, ARQT or CYTK?

Summary

How does Arcutis Biotherapeutics compare to Krystal Biotech?

Which has more risk & volatility, ARQT or KRYS?

Do analysts rate ARQT or KRYS?

Does the media favor ARQT or KRYS?

Which has preferable earnings and valuation, ARQT or KRYS?

Do insiders & institutionals have more ownership in ARQT or KRYS?

Is ARQT or KRYS more profitable?

Summary

How does Arcutis Biotherapeutics compare to ImmunityBio?

Do insiders and institutionals have more ownership in IBRX or ARQT?

Is IBRX or ARQT more profitable?

Which has more volatility & risk, IBRX or ARQT?

Do analysts recommend IBRX or ARQT?

Which has better valuation and earnings, IBRX or ARQT?

Does the media favor IBRX or ARQT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools